China Nuokang Bio-Pharma Falls on NY Debut
By wchung | 09 Jun, 2026
Shares of China Nuokang Bio-Pharmaceutical Inc. fell nearly 4 percent in their trading debut Thursday after pricing at $9 per American depositary share, below their expected range.
The China-based biopharmaceutical company, which specializes in blood and cardiovascular treatments, had expected the initial public offering of 5 million ADSs to price between $10 and $12.
The company said net proceeds from the offering totaled about $32.9 million. The company plans to use the funds to grow its sales and marketing platform, for new acquisitions, for research and to expand manufacturing facilities.
Shares, which trade under the symbol “NKBP” on the Nasdaq, fell 33 cents, or 3.7 percent, to close at $8.67 with about 2.3 million shares changing hands during the session.
12/10/2009 4:53 PM NEW YORK (AP)
Recent Articles
- China Prepares $295 Billion Plan to Fund Nationwide AI Buildout
- Musk's Starlink Far Ahead of Bezos' Amazon in Wi-Fi Rush by Airlines
- Volvo-Parent Geely's Driver Assistance System Certified by EU
- Xi Embraces North Korea As Key Ally in Contest with US
- Samsung Electronics Considers Building Chip Packaging Plant
- How Honda’s CEO Survived a Putsch by the Old Guard
- Chinese Hackers' Spying Poses Biggest Threat to Tech Firms Says CrowdStrike
- J.M. Smucker Upbeat on Annual Profits on Higher Coffee Prices, At-Home Dining
- Embraer's Electric Aircraft Subsidiary Provides Revenue Boost
- Oil Helped Drive Record US Exports in April